SubHero Banner

Pomalyst® (pomalidomide) – New orphan indication

May 15, 2020 - Bristol Myers Squibb announced the FDA approval of Pomalyst (pomalidomide), for the treatment of adult patients with acquired immunodeficiency syndrome (AIDS)-related Kaposi sarcoma after failure of highly active antiretroviral therapy (HAART) and Kaposi sarcoma in adult patients who are human immunodeficiency virus (HIV)-negative.

Download PDF